NCT03455829View on ClinicalTrials.gov

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

December 14, 2021

Study Completion Date

February 14, 2022

Conditions
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
Interventions
DRUG

G1T38

CDK 4/6 inhibitor

DRUG

Osimertinib

EGFR TKI; 80 mg

Trial Locations (8)

22301

Virginia Cancer Specialists, Fairfax

33136

Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine Fox Building, Suite 200 G, Miami

33612

Mofitt Cancer Center, Tampa

48109

Univ. of Michigan Hospitals, Ann Arbor

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

90211

Beverly Hills Cancer Center, Beverly Hills

90404

UCLA Medical Center, Division of Hematology/Oncology/Clinical Research Unit, Santa Monica

95403

St Joseph Heritage Healthcare, Santa Rosa

Sponsors
All Listed Sponsors
lead

G1 Therapeutics, Inc.

INDUSTRY

NCT03455829 - G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter